SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 03 03 2021
accepted: 11 07 2021
entrez: 23 7 2021
pubmed: 24 7 2021
medline: 3 8 2021
Statut: epublish

Résumé

Since the first case of COVID-19 in December 2019 in Wuhan, China, SARS-CoV-2 has spread worldwide and within a year and a half has caused 3.56 million deaths globally. With dramatically increasing infection numbers, and the arrival of new variants with increased infectivity, tracking the evolution of its genome is crucial for effectively controlling the pandemic and informing vaccine platform development. Our study explores evolution of SARS-CoV-2 in a representative cohort of sequences covering the entire genome in the United States, through all of 2020 and early 2021. Strikingly, we detected many accumulating Single Nucleotide Variations (SNVs) encoding amino acid changes in the SARS-CoV-2 genome, with a pattern indicative of RNA editing enzymes as major mutators of SARS-CoV-2 genomes. We report three major variants through October of 2020. These revealed 14 key mutations that were found in various combinations among 14 distinct predominant signatures. These signatures likely represent evolutionary lineages of SARS-CoV-2 in the U.S. and reveal clues to its evolution such as a mutational burst in the summer of 2020 likely leading to a homegrown new variant, and a trend towards higher mutational load among viral isolates, but with occasional mutation loss. The last quartile of 2020 revealed a concerning accumulation of mostly novel low frequency replacement mutations in the Spike protein, and a hypermutable glutamine residue near the putative furin cleavage site. Finally, end of the year data and 2021 revealed the gradual increase to prevalence of known variants of concern, particularly B.1.1.7, that have acquired additional Spike mutations. Overall, our results suggest that predominant viral genomes are dynamically evolving over time, with periods of mutational bursts and unabated mutation accumulation. This high level of existing variation, even at low frequencies and especially in the Spike-encoding region may become problematic when super-spreader events, akin to serial Founder Events in evolution, drive these rare mutations to prominence.

Identifiants

pubmed: 34297786
doi: 10.1371/journal.pone.0255169
pii: PONE-D-21-07041
pmc: PMC8301627
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0255169

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478625
J Immunol. 2015 Nov 15;195(10):4565-70
pubmed: 26546688
Nat Struct Mol Biol. 2020 Oct;27(10):959-966
pubmed: 32908316
Mol Biol Evol. 2020 Feb 1;37(2):599-603
pubmed: 31633786
Bioinformatics. 2019 May 15;35(10):1763-1765
pubmed: 30295730
Viruses. 2020 Sep 27;12(10):
pubmed: 32992592
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8127-32
pubmed: 12034870
Wellcome Open Res. 2021 May 19;6:121
pubmed: 34095513
Annu Rev Biochem. 2010;79:321-49
pubmed: 20192758
J Hum Genet. 2020 Dec;65(12):1075-1082
pubmed: 32699345
PeerJ. 2017 Dec 6;5:e4136
pubmed: 29230368
Nat Commun. 2020 Jun 12;11(1):2971
pubmed: 32532990
Virology. 2008 Sep 30;379(2):175-80
pubmed: 18678384
Sci Transl Med. 2021 Jun 2;13(596):
pubmed: 33979301
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Nucleic Acids Res. 2012 Jan;40(1):e2
pubmed: 22013163
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Curr Opin HIV AIDS. 2014 May;9(3):224-34
pubmed: 24714565
Genetics. 2004 Jul;167(3):1041-6
pubmed: 15280221
Infect Genet Evol. 2020 Nov;85:104445
pubmed: 32615316
Arch Virol. 2020 Oct;165(10):2341-2348
pubmed: 32737584
Cell Mol Immunol. 2020 Jun;17(6):621-630
pubmed: 32415260
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
Nat Commun. 2020 Nov 18;11(1):5885
pubmed: 33208793
Nat Commun. 2015 Apr 21;6:6881
pubmed: 25898173
Nature. 2020 Aug;584(7821):353-363
pubmed: 32659783
PLoS One. 2020 Oct 2;15(10):e0237689
pubmed: 33006981
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Cell Host Microbe. 2021 Mar 10;29(3):489-502.e8
pubmed: 33548198
Nucleic Acids Res. 2020 Apr 17;48(7):3734-3746
pubmed: 32095818
Nucleic Acids Res. 2020 Feb 20;48(3):1435-1450
pubmed: 31863583
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Bioinformatics. 2015 Dec 15;31(24):3997-9
pubmed: 26315911
Protein J. 2020 Jun;39(3):198-216
pubmed: 32447571
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165878
pubmed: 32544429
BMJ. 2021 Feb 5;372:n359
pubmed: 33547053
PLoS Pathog. 2020 Aug 14;16(8):e1008718
pubmed: 32797103
J Infect. 2020 Jul;81(1):e24-e27
pubmed: 32283146
Nat Commun. 2019 May 28;10(1):2342
pubmed: 31138817
Res Sq. 2020 Aug 11;:
pubmed: 32818213
Nat Struct Mol Biol. 2011 Feb;18(2):230-6
pubmed: 21258325
Nat Commun. 2018 May 16;9(1):1948
pubmed: 29769532
MMWR Morb Mortal Wkly Rep. 2020 Oct 09;69(40):1450-1456
pubmed: 33031361
mSphere. 2020 Jun 24;5(3):
pubmed: 32581081
mSystems. 2020 May 5;5(3):
pubmed: 32371472
Mol Biol Evol. 2007 Oct;24(10):2334-43
pubmed: 17703053
J Med Virol. 2020 Jun;92(6):584-588
pubmed: 32083328
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
Bioinformatics. 2015 Nov 15;31(22):3718-20
pubmed: 26209431
Comput Struct Biotechnol J. 2020;18:3402-3414
pubmed: 33200028
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
J Virol. 2020 Nov 9;94(23):
pubmed: 32938769
J Virol. 2012 Apr;86(7):3777-86
pubmed: 22301159
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Virus Genes. 2021 Oct;57(5):413-425
pubmed: 34251592
Genes (Basel). 2020 Aug 07;11(8):
pubmed: 32784710
Genetics. 2012 May;191(1):171-81
pubmed: 22367031
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9436-41
pubmed: 26159422
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):
pubmed: 33472860
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
Sci Adv. 2020 Jun 17;6(25):eabb5813
pubmed: 32596474
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Lancet Respir Med. 2021 Apr;9(4):333-335
pubmed: 33524316
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99
pubmed: 33476315

Auteurs

Rafail Nikolaos Tasakis (RN)

Division of Immune Diversity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.

Georgios Samaras (G)

Division of Immune Diversity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Program of Translational Medical Research, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.

Anna Jamison (A)

The Nightingale-Bamford School, New York, NY, United States of America.

Michelle Lee (M)

Cornell University, Ithaca, NY, United States of America.

Alexandra Paulus (A)

The Nightingale-Bamford School, New York, NY, United States of America.

Gabrielle Whitehouse (G)

The Nightingale-Bamford School, New York, NY, United States of America.

Laurent Verkoczy (L)

San Diego Biomedical Research Institute (SDBRI), San Diego, CA, United States of America.

F Nina Papavasiliou (FN)

Division of Immune Diversity, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Marilyn Diaz (M)

San Diego Biomedical Research Institute (SDBRI), San Diego, CA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH